Efficacy and Safety of BGG492 in the Treatment of Migraine

A Multi-centre, Randomized, Double-blind, Parallel Group, Active and Placebo Controlled, Proof of Concept Study in Patients With Acute Migraine to Assess the Efficacy, Safety and Tolerability of Single Oral Doses of BGG492

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

Inclusion Criteria:

• Diagnosis of moderate to severe migraine for at least 1 year
• At least 1 migraine episode, but not more 15 migraine days per month
• Past use of triptans
• Migraine onset before 50 years of age

Exclusion Criteria:

• Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine.
• More than 6 non-migraine headaches per month
• Patients receiving migraine prophylaxis treatment
• Patients receiving regular treatment with psychoactive drugs
• Smokers
• Patients with a very high or low body weight Other protocol-defined inclusion/exclusion criteria may apply